早期乳腺癌保乳术后大分割放疗Ⅱ期临床研究——中期安全性及有效性分析

doi:10.19401/j.cnki.1007-3639.2018.10.008

中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (10): 769-775.doi: 10.19401/j.cnki.1007-3639.2018.10.008

早期乳腺癌保乳术后大分割放疗Ⅱ期临床研究——中期安全性及有效性分析

罗菊锐¹，陈星星¹，杨昭志¹，张丽¹，马金利¹，梅欣¹，邵志敏²，郭小毛¹，俞晓立¹

1. 复旦大学附属肿瘤医院放疗科，复旦大学上海医学院肿瘤学系，上海 200032 ；
2. 复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系，上海 200032

出版日期:2018-10-30 发布日期:2018-11-12
通信作者: 俞晓立 E-mail：stephanieyxl@hotmail.com
基金资助:
上海市卫生和计划生育委员会科研课题（201440425）；国家自然科学基金青年项目（81402525）。

A phase Ⅱ study of hypofractionated whole breast irradiation in patients with early stage breast cancer after breast-conserving surgery: safety and efficacy analysis

LUO Jurui¹, CHEN Xingxing¹, YANG Zhaozhi¹, ZHANG Li¹, MA Jinli¹, MEI Xin¹, SHAO Zhimin², GUO Xiaomao¹, YU Xiaoli¹

1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Published:2018-10-30 Online:2018-11-12
Contact: YU Xiaoli E-mail: stephanieyxl@hotmail.com

摘要/Abstract

摘要： 背景与目的：乳腺癌保乳术后全乳大分割放疗的安全性和有效性在多项随机临床试验中已经得到证实，但全乳大分割瘤床同期加量的放疗模式目前仍不明确。本研究旨在探讨中国人群早期乳腺癌保乳术后大分割放疗同期瘤床加量的安全性及有效性。方法：前瞻性入组保乳术后切缘阴性、病理诊断为浸润性癌、分期pT_1-2N₀M₀、术中瘤床钛夹标记的患者接受全乳大分割同期瘤床加量放疗（ClinicalTrail.gov: NCT02617043）。放疗处方剂量为全乳计划靶体积（planned target volume，PTV） 40 Gy/15次/3周，同期瘤床加量至48 Gy/15次/3周。放疗后评估急性不良反应、美容效果以及预后。结果：2015年1月—2016年8月，共计358例患者前瞻性连续性入组本研究。患者中位年龄45岁（25~71岁），71.2%（255例）为绝经前的年轻女性，其中T1和T2患者分别为276例（77.1%）和82例（22.9%）。放疗期间及放疗后3个月内，53.6%和8.1%的患者出现Ⅰ~Ⅱ度的放射性皮炎，主要表现为放疗区红斑（38.8%）以及放疗后干性脱皮（41.3%）。13例（3.6%）患者出现湿性脱皮，主要位于乳头、乳晕区，无Ⅲ度以上放射性皮炎。4例Ⅰ度放射性肺炎，1例Ⅲ度放射性肺炎。美容效果自评“极好”和“好”率分别为37.0%和44.8%。中位随访28.3个月（6.0~40.7个月），3例患者出现局部区域复发，4例远处转移（2例合并复发），2年无病生存率（disease-free survival，DFS）为98.6%。结论：对于早期乳腺癌保乳术后患者，全乳大分割同期瘤床加量放疗不良反应轻、耐受性好，具有一定的安全性及有效性，其晚期不良反应以及对疾病局部控制的有效性仍需长期随访来证实。

关键词: 乳腺癌, 大分割放疗, 瘤床加量, 不良反应

Abstract: Background and purpose: The long-term safety and efficacy of hypofractionated whole-breast irradiation (HFWBI) have been well established in randomized trials, but little is known about the effect of HF-WBI with simultaneous boost of the tumor bed. This study aimed to assess the safety and efficacy of HF-WBI with simultaneous tumor bed boost after breast-conserving surgery in Chinese population. Methods: Patients with pT_1-2N₀M₀invasive breast cancer, negative margins, clips marked tumor bed after breast-conserving surgery were prospectively and consecutively enrolled in this study. All patients received total dose of 40 Gy/15 Fx/3 weeks for whole breast, combined with simultaneous boost of tumor bed, total dose of 48 Gy/15 Fx/3 weeks. The acute radiotherapy-induced toxicities, cosmetic effect and prognosis were followed up after the treatment. Results: From Jan. 2015 to Aug. 2016, 358 patients were enrolled in the study. The median age was 45 years (range, 25-71 years), and 71.2% patients were premenopausal young women. A total of 276 (77.1%) patients had T1 tumors, and 82 (22.9%) patients had T2. During the treatment, 53.6% and 8.1% patients had Grade 1 and Grade 2 radiation dermatitis, respectively, mainly manifested as skin erythema (38.8%) or desquamation (41.3%). Thirteen patients experienced moist desquamation mainly in the nipple and areola area. No grade≥3 radiation dermatitis was observed. Four patients had Grade 1 and one patient had Grade 3 radiation pneumonitis. 37.0% and 44.8% patients’ self-assessed cosmetic effects were “Excellent” and “Good”, respectively. With a median follow-up time of 28.3 months (range: 6.0-40.7 months), three patients experienced locoregional recurrence and four patients had distant metastasis (two of them with locoregional recurrence). The 2-year disease-free survival was 98.6%. Conclusion: Hypofractionated whole-breast irradiation combined with simultaneous boost of the tumor bed has few acute toxic effects and can be well tolerated in patients with early stage breast cancer after breast-conserving surgery. Long-term follow-up is needed to confirm its late toxic effects and efficacy of disease
control.

Key words: Breast cancer, Hypofractionated whole breast irradiation, Tumor bed boost, Side effects

罗菊锐,陈星星,杨昭志,等. 早期乳腺癌保乳术后大分割放疗Ⅱ期临床研究——中期安全性及有效性分析[J]. 中国癌症杂志, 2018, 28(10): 769-775.

LUO Jurui, CHEN Xingxing, YANG Zhaozhi, et al. A phase Ⅱ study of hypofractionated whole breast irradiation in patients with early stage breast cancer after breast-conserving surgery: safety and efficacy analysis[J]. China Oncology, 2018, 28(10): 769-775.

[1]	章箎, 陈佳慧, 林瑾仪, 王妍, 张斯加, 朱玮, 程蕾蕾. 一种新型《乳腺癌治疗相关心血管毒性临床评分表》的价值分析[J]. 中国癌症杂志, 2022, 32(1): 54-60.
[2]	金奕滋, 林明曦, 张剑. DNA损伤应答缺陷作为乳腺癌治疗靶点的研究进展[J]. 中国癌症杂志, 2022, 32(1): 61-67.
[3]	《中国乳腺癌新辅助治疗专家共识（2022年版）》专家组. 中国乳腺癌新辅助治疗专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(1): 80-89.
[4]	张小艳, 李清祥, 刘　勇, 李　航, 仇丽娟, 封欣然, 谭立明 . HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究[J]. 中国癌症杂志, 2021, 31(9): 783-788.
[5]	曹爱玲, 曹　喆, 周　剑. 多西他赛联合胸腺肽α1对大鼠乳腺癌免疫微环境中Treg数量的影响及其机制研究[J]. 中国癌症杂志, 2021, 31(9): 799-806.
[6]	姚　嘉, 李冠乔, 杨时平, 苏慧銮 . Hsa-miR-98-5p/DKK3信号轴对乳腺癌细胞生物学行为的影响[J]. 中国癌症杂志, 2021, 31(9): 807-816.
[7]	丛斌斌, 王永胜. 激素受体阳性早期乳腺癌治疗现状与挑战[J]. 中国癌症杂志, 2021, 31(8): 689-696.
[8]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[9]	丁高峰, 郭雷鸣, 陆寓非. 乳腺癌患者HER2和BRCA1表达与放疗敏感性的关系研究[J]. 中国癌症杂志, 2021, 31(7): 589-595.
[10]	金优萍, 李录英, 周　平. 长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究[J]. 中国癌症杂志, 2021, 31(7): 596-604.
[11]	谢金芳, 曹春雨, 任　雪, 田家俊, 吕亚丰, 黄晓飞 . 萝卜硫素对小鼠乳腺癌4T1细胞上皮-间质转化、增殖和迁移的影响研究[J]. 中国癌症杂志, 2021, 31(7): 605-615.
[12]	曾　峰, 李　丹, 邵鑫鑫, 张能英, 陈星翰, 程晓明 . 基于SEER数据库构建1~2枚淋巴结阳性且乳房全切的老年早期乳腺癌患者不同腋窝手术方式的生存预测模型[J]. 中国癌症杂志, 2021, 31(4): 323-329.
[13]	王春建 , 聂　刚 , 毛　艳 . TRIP6在乳腺癌中的作用及其机制研究[J]. 中国癌症杂志, 2021, 31(3): 161-169.
[14]	义维丽, 赵文成, 黄东宁, 覃　莉, 吴新天, 周　斐, 吴凤英 . PD-1单抗治疗非小细胞肺癌相关不良反应及其与疗效的相关性分析[J]. 中国癌症杂志, 2021, 31(3): 203-211.
[15]	胡喜娥, 杨振宇, 薛景毅, 杨　平, 彭书甲, 袁利娟, 包国强 . 单细胞测序在三阴性乳腺癌新辅助化疗中的应用研究进展[J]. 中国癌症杂志, 2021, 31(3): 221-226.

早期乳腺癌保乳术后大分割放疗Ⅱ期临床研究——中期安全性及有效性分析

A phase Ⅱ study of hypofractionated whole breast irradiation in patients with early stage breast cancer after breast-conserving surgery: safety and efficacy analysis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价